Perspective Therapeutics
CATX
138 hedge funds and large institutions have $333M invested in Perspective Therapeutics in 2026 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 42 increasing their positions, 28 reducing their positions, and 23 closing their positions.
217% more capital invested
Capital invested by funds: $105M → $333M (+$228M)
214% more call options, than puts
Call options by funds: $1.89M | Put options by funds: $603K
104% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 23
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 28
20.93% more ownership
Funds ownership: 49.21% → 70.14% (+21%)
18% more funds holding
Funds holding: 117 → 138 (+21)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$33.4M |
| 2 |
CC
Commodore Capital
New York
|
+$26.8M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$14.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$13.9M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$12.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$6.3M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.71M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$1.54M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.12M |
| 5 |
Jane Street
New York
|
-$1.12M |
CATX Hedge Fund Activity: Q1 2026 in Review
138 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q1 2026, worth a combined $333M — up 217% from $105M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new CATX positions and 23 closed out — a net gain of 24 holders — while 42 added to existing stakes and 28 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $33.4M. The largest seller was Morgan Stanley, cutting an estimated $6.3M.
- 138 institutional investors held Perspective Therapeutics (CATX) as of Q1 2026, up from 117 in Q4 2025.
- Funds reported $333M of Perspective Therapeutics stock for Q1 2026, up 217% quarter-over-quarter.
- 47 funds opened new Perspective Therapeutics positions in Q1 2026 and 23 closed out, a net change of +24 holders.
- The largest Perspective Therapeutics buyer in Q1 2026 was TCG Crossover Management, an estimated $33.4M added.
- The largest Perspective Therapeutics seller in Q1 2026 was Morgan Stanley, an estimated $6.3M sold.
Based on aggregated 13F filings for Q1 2026.